Endometrial squamous cell carcinoma

Summary

Endometrial squamous cell carcinoma (MONDO:0006198) is a cancer and 6 clinical trials. Top therapeutic interventions include cisplatin, nintedanib, and brivanib alaninate. A subtype of endometrial carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endometrial squamous cell carcinoma
Mondo ID	MONDO:0006198
EFO	EFO:1000240
DOID	DOID:5533
ICD-11	1130568776
NCIT	C8719
UMLS	C1333396
MedGen	234217
Anatomy (UBERON)	UBERON:0001295
Is cancer (heuristic)	yes

Also known as: endometrial squamous cell carcinoma · endometrium squamous cell carcinoma · squamous cell carcinoma of endometrium · squamous cell carcinoma of the endometrium

Data availability: 2 cell lines.

Disease family

This is a subtype of endometrial carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › endometrial carcinoma › endometrial squamous cell carcinoma

Related subtypes (6): uterine corpus endometrial carcinoma, endometrial transitional cell carcinoma, endometrium carcinoma in situ, endometrium adenocarcinoma, endometrial small cell carcinoma, endometrial undifferentiated carcinoma

Subtypes (1): endometrial adenosquamous carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00492778	PHASE2	UNKNOWN	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00888173	PHASE2	COMPLETED	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887	PHASE2	COMPLETED	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01642082	PHASE2	COMPLETED	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00575952	PHASE1	COMPLETED	Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
NCT01440998	PHASE1	COMPLETED	Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	2
NINTEDANIB	4	1
BRIVANIB ALANINATE	3	1
DALANTERCEPT	3	1